Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 42, Issue 3, 2011, Pages 502-508

  Pourmohammadi, B ^a,b   Motazedian, M H ^a   Handjani, F ^a   Hatam, G H R ^c   Habibi, S ^d   Sarkari, B ^e  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SEMNAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e NONE

Author keywords

Glucantime; Iran; Treatment; Unresponsiveness; Zoonotic cutaneous leishmaniasis

Indexed keywords

EID: 79961052350     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aransay AM, Scoulica E, Tselentis Y. Detection and identification of Leishmania DNA within naturally infected sand flies by PCR on minicircle kinetoplastic DNAAppl Environ Microbiol 2000; 66: 1933-8. (Pubitemid 30253714)
2. Beheshti M, Ghotbi Sh, Amirizade S. Therapeutic and adverse effects of glucantime used for treatment of cutaneous LeishmaniasisShiraz E-Medical J 2007; 8: 155-61.
3. Bailey MS, Lockwood DNJ. Cutaneous leishmaniasis. Clin Dermatol 2007; 25: 203-11. (Pubitemid 46366603)
4. Blum JA, Hatz CF. Treatment of cutaneous leishmaniasis in travelersJ Travel Med 2009; 16: 123-31.
5. Boggild AK, Miranda-Verastegui C, Espinosa D, et al. Evaluation of a microculture method for isolation of Leishmania parasites from cutaneous lesions of patients in PeruJ Clin Microbiol 2007; 45: 3680-4. (Pubitemid 350156866)
6. Decuypere S, Rijal S, Yardley V, et al. Gene expression analysis of the mechanism of natural Sb V resistance in Leishmania donovani isolates from NepalAntimicrob Agents Chemother 2005; 49: 4616-21. (Pubitemid 41552591)
7. Dowlati Y. Cutaneous leishmaniasis: clinical aspectsClin Dermatol 1996; 14: 425-31.
8. Firdous R. Yasinzai M. Ranja K. Efficacy of glucantime in the treatment of old World cutaneous leishmaniasis. Int J Dermatol 2009; 48: 758-62. 21.
9. Frézard F, Demicheli C, Ribeiro RR. Pentavalent antimonials: new perspectives for old drugsMolecules 2009; 14: 2317-36.
10. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Ouellette M. Unresponsiveness to glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasitesPLoS Med 2006; 3: e162.
11. Hatam, G R. Hosseini, SM H, Ardehali S. Isoenzyme studies in characterization of Leishmania isolated in Iran. IJMS 1999; 24: 110-5.
12. Lianos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in PeruClin Infect Dis 2008; 46: 223-31. (Pubitemid 351269161)
13. Lucumi A, Robledo S, Gama V, Saravia NG. Sensitivity of Leishmania viannia panamensis to pentavalent antimony is correlated with the formation of cleavable DNAprotein complexesAntimicrob Agents Chemother 1998; 42: 1990-5. (Pubitemid 28363081)
14. Mohebali A M, Fotouhi B, Hooshmand Z, et al. Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis ZCL by a randomized clinical trial in IranActa Trop 2007; 103: 33-40.
15. Motazedian H, Noamanpoor B, Ardehali S. Characterization of Leishmania parasites isolated from provinces of the Islamic Republic of IranEast Mediterr Health J. 2002; 8: 338-44. (Pubitemid 39162523)
16. Nilforoushzadeh MA, Jaffary F, Ansari N, Siadat AH, Nilforoushan Z, Firouz A. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasisJ Vector Borne Dis 2008; 45: 287-91.
17. Ouellette M, Drummelsmith J, Papadopoulou B. Leishmaniasis: drugs in the clinic, resistance and new developmentsDrug Resist Updat 2004; 7: 257-66. (Pubitemid 39469098)
18. Papadopoulou B, Kundig C, Singh A, Ouellette M. Drug resistance in Leishmania: similarities and differences to other organismsDrug Resist Updat 1998; 1: 266-78.
19. Pouran L, Fakhrozaman P, Amir HS, Parisa N, Toktam M. Efficacy of cryotherapy versus intralesional meglumine antimoniate Glucantime for treatment of cutaneous leishmaniasis in childrenAm J Trop Med Hyg 2009; 80: 172-5.
20. Pourmohammadi B, Motazedian MH, Kalantari M. Rodent infection with Leishmania in a new focus of human cutaneous leishmaniasis, in northern IranAnn Trop Med Parasitol 2008; 102: 127-33. (Pubitemid 351767940)
21. Santos DO, Coutinho CER, Madeira MF, et al. Leishmaniasis treatment- a challenge that remains: a reviewParasitol Res 2008; 103: 1-10.
22. Sereno D, Da Silva AC, Mathieu-Daude F, Ouaissi A. Advances and perspectives in Leishmania cell based drug-screening proceduresParasitol Int 2007; 56: 3-7.
23. Soto J, Valda-Rodriquez L, Toledo J, et al. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasisAm J Trop Med Hyg 2004; 71: 577-81. (Pubitemid 39601154)
24. Zerehsaz F, Salmanpour R, Handjani F, et al. A double-blind randomized clinical trial of a topical herbal extract Z-HE vs. systemic meglumine antimoniate for the treatment of cutaneous leishmaniasis in IranInt J Dermatol 1999; 38: 610-2. (Pubitemid 29404794)